GW Pharmaceuticals (NASDAQ:GWPH) has had a very successful launch of “Epidiolex” in the USA. This, along with its promising pipeline, has been the main reason for the stock price gains it had enjoyed this year.
However, recent news that the U.K. NHS (National Health Service) would not currently approve Epidiolex (or “Epidyolex” as it is trademarked in Europe) represent a barrier to their monetisation plans for Europe.
The news means Epidiolex will not be available in the U.K. in the short to medium term even after EMA approval. Costing model problems may apply similarly in other European countries outside the U.K. Meanwhile, the company awaits final approval for Epidiolex from the EMA (European Medicines Agency).
An additional possible drawback for GW Pharma is that authorities in Europe may increasingly approve natural cannabis products in their raw form rather than in